Hjem › Marginalzone-lymfom › Ohio
Marginalzone-lymfom kliniske forsøg i Ohio
13 studier for Marginalzone-lymfom søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
Epco, Zanu, Ritux for R/R FL or MZL
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06563596Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Licking Memorial Hospital, Newark
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07225439Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT06708897A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. jul. 2026 · NCT05131022Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
- Ohio Health Riverside Methodist Hospital, Columbus
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 22. jun. 2026 · NCT05700149Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT05544019Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- University of Cincinnati, Cincinnati
- Ohio State University, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT04775745AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Taylor Cancer Research Center, Maumee
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. dec. 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2025 · NCT05780034Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.